Evaluation of the implementation of whole genome sequencing for diagnosis, detection of resistance and choice of therapeutic regimen for Tuberculosis in clinical practice conditions

Instituto de Ciências Biomédicas da Universidade de São Paulo - ICB/USP0 个研究点开始时间: 2024年8月7日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Both sexes. Be a patient of at least one of the six medical centers participating in this study during the data collection period. Patients with treatment failure or relapse in whom antimicrobial resistance is suspected, but diagnostic resistance tests have not been performed or who have a negative result for rifampicin resistance on the Xpert® MTB/RIF Ultra. Patients with a positive test for rifampicin resistance by Xpert® MTB/RIF Ultra. Patients with a negative test for resistance to rifampicin by the Xpert® MTB/RIF Ultra, but positive for resistance to any of the first-line drugs by the Hain ribbon genotypic tests (GenoType MTBDR). Patients with relapse and previous diagnosis of resistant Tuberculosis

•Extrapulmonary tuberculosis at the time of diagnosis or diagnosed during the study. Negative culture. Co-infection with nontuberculous mycobacteria. Patients who change treatment centers during the study. Patients who wish to abandon the study

发起方

Instituto de Ciências Biomédicas da Universidade de São Paulo - ICB/USP